FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies

Reasearch, , , , , ,

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA) approval of its in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test and its first two companion diagnostic (CDx) indications. This single test interrogates over 500 genes to profile a patient’s solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment. Continue reading

Related posts:

  1. Large-scale proteomics in population-based studies from UK and Iceland
  2. Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
  3. International Collaboration to Improve Cancer Care in Sub-Saharan Africa Focuses on Resources for Children’s Cancers
  4. Healthy.io Awarded Three New U.S. Patents for Wound-Image Technology